Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
uniQure N.V. (QURE)
:QURE
Holding QURE?
Track your performance easily
QURE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.73 - $19.18
Previous CloseN/A
Volume1.49M
Average Volume (3M)3.67M
Market Cap
$759.35M
Enterprise Value$299.22M
Total Cash (Recent Filing)$132.50M
Total Debt (Recent Filing)$19.63M
Price to Earnings (P/E)―
Beta1.88
Next Earnings
Mar 03, 2025EPS Estimate
-0.65Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.96
Shares Outstanding53,437,393
10 Day Avg. Volume1,402,157
30 Day Avg. Volume3,669,627
Standard Deviation0.32
R-Squared0.00467
Alpha0.00310
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)23.85
Price to Cash Flow (P/CF)-4.70
P/FCF Ratio0.00
Enterprise Value/Market Cap0.39
Enterprise Value/Revenue10.47
Enterprise Value/Gross Profit135.09
Enterprise Value/Ebitda-1.70
Forecast
1Y Price Target
$29.59Price Target Upside108.23% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
uniQure News
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessAMT-130 showed statistically significant and dose-dependent slowing of disease progression and a reduction in neurofilament light chain at 24 months.
FDA AlignmentQURE announced they have reached regulatory alignment on a path to accelerated approval with the FDA that will not require them to run an additional study, removing the overhang on the stock for many investors.
Regulatory ApprovalUniQure disclosed a positive regulatory update for AMT-130 in Huntington’s disease, with an agreement on key elements of an Accelerated Approval pathway.
Bears Say
Market CompetitionThe development landscape for Huntington's disease therapies is increasingly crowded, posing competition challenges.
Operational EfficiencyQURE reduced their global workforce with the elimination of approximately 65% or 300 roles across the organization.
Regulatory ChallengesThere is regulatory uncertainty surrounding the potential path for AMT-130.
---
Ownership Overview
2.46% Insiders
8.54% Mutual Funds
0.40% Other Institutional Investors
84.25% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
QURE FAQ
What was uniQure N.V.’s price range in the past 12 months?
uniQure N.V. lowest stock price was $3.73 and its highest was $19.18 in the past 12 months.
What is uniQure N.V.’s market cap?
uniQure N.V.’s market cap is $759.35M.
When is uniQure N.V.’s upcoming earnings report date?
uniQure N.V.’s upcoming earnings report date is Mar 03, 2025 which is in 44 days.
How were uniQure N.V.’s earnings last quarter?
uniQure N.V. released its earnings results on Nov 05, 2024. The company reported -$0.91 earnings per share for the quarter, beating the consensus estimate of -$0.993 by $0.083.
Is uniQure N.V. overvalued?
According to Wall Street analysts uniQure N.V.’s price is currently Undervalued.
Does uniQure N.V. pay dividends?
uniQure N.V. does not currently pay dividends.
What is uniQure N.V.’s EPS estimate?
uniQure N.V.’s EPS estimate is -0.65.
How many shares outstanding does uniQure N.V. have?
uniQure N.V. has 53,437,393 shares outstanding.
What happened to uniQure N.V.’s price movement after its last earnings report?
uniQure N.V. reported an EPS of -$0.91 in its last earnings report, beating expectations of -$0.993. Following the earnings report the stock price went up 8.993%.
Which hedge fund is a major shareholder of uniQure N.V.?
Among the largest hedge funds holding uniQure N.V.’s share is Moore Capital Management LP. It holds uniQure N.V.’s shares valued at 493K.
---
uniQure Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$29.59 (108.23% Upside)
$29.59 (108.23% Upside)
Blogger Sentiment
Bullish
QURE Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 502.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $39.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.8%
Last 30 Days ▲ 19.6%
Last 30 Days ▲ 19.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
141.66%
12-Months-Change
Fundamentals
Return on Equity
-147.56%
Trailing 12-Months
Asset Growth
-25.90%
Trailing 12-Months
Company Description
uniQure N.V.
uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.
---
QURE Stock 12 Month Forecast
Average Price Target
$29.59
▲(108.23% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Sarepta Therapeutics
―
Ultragenyx Pharmaceutical
―
Alnylam Pharma
―
Intellia Therapeutics
―
Editas Medicine
―
Best Analysts Covering QURE
1 Year
1 Year Success Rate
10/21 ratings generated profit
1 Year Average Return
+22.04%
reiterated a buy rating last month
Copying Patrick Trucchio's trades and holding each position for 1 Year would result in 47.62% of your transactions generating a profit, with an average return of +22.04% per trade.
---